Dechra Pharmaceuticals Dirección
Dirección controles de criterios 4/4
El CEO de Dechra Pharmaceuticals' es Ian Page , nombrado en Nov 2001, tiene una permanencia de 22.17 años. compensación anual total es £1.04M, compuesta por 59.9% salario y 40.1% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.36% de las acciones de la empresa, por valor de £15.64M. La antigüedad media del equipo directivo y de la junta directiva es de 4.8 años y 4.3 años, respectivamente.
Información clave
Ian Page
Chief Executive Officer (CEO)
UK£1.0m
Compensación total
| Porcentaje del salario del CEO | 59.9% |
| Permanencia del CEO | 22.2yrs |
| Participación del CEO | 0.4% |
| Permanencia media de la dirección | 4.8yrs |
| Promedio de permanencia en la Junta Directiva | 4.3yrs |
Actualizaciones recientes de la dirección
Recent updates
Dechra Pharmaceuticals (LON:DPH) Takes On Some Risk With Its Use Of Debt
May 31
A Look At The Intrinsic Value Of Dechra Pharmaceuticals PLC (LON:DPH)
Mar 28We Think Dechra Pharmaceuticals (LON:DPH) Is Taking Some Risk With Its Debt
Mar 02Dechra Pharmaceuticals' (LON:DPH) Dividend Will Be Increased To £0.125
Mar 02Estimating The Intrinsic Value Of Dechra Pharmaceuticals PLC (LON:DPH)
Dec 09Dechra Pharmaceuticals (LON:DPH) Is Increasing Its Dividend To £0.3289
Oct 06Dechra Pharmaceuticals (LON:DPH) Is Paying Out A Larger Dividend Than Last Year
Sep 22Dechra Pharmaceuticals (LON:DPH) Will Pay A Larger Dividend Than Last Year At £0.3289
Sep 08Estimating The Intrinsic Value Of Dechra Pharmaceuticals PLC (LON:DPH)
Aug 18Do Dechra Pharmaceuticals' (LON:DPH) Earnings Warrant Your Attention?
Aug 02These 4 Measures Indicate That Dechra Pharmaceuticals (LON:DPH) Is Using Debt Reasonably Well
Jun 10Calculating The Fair Value Of Dechra Pharmaceuticals PLC (LON:DPH)
May 08Do Dechra Pharmaceuticals's (LON:DPH) Earnings Warrant Your Attention?
Apr 22Dechra Pharmaceuticals (LON:DPH) Is Increasing Its Dividend To UK£0.12
Feb 23Is Dechra Pharmaceuticals PLC (LON:DPH) Expensive For A Reason? A Look At Its Intrinsic Value
Jan 29Is Now The Time To Put Dechra Pharmaceuticals (LON:DPH) On Your Watchlist?
Jan 11Here's Why Dechra Pharmaceuticals (LON:DPH) Can Manage Its Debt Responsibly
Dec 04It Looks Like Shareholders Would Probably Approve Dechra Pharmaceuticals PLC's (LON:DPH) CEO Compensation Package
Oct 15Dechra Pharmaceuticals' (LON:DPH) Upcoming Dividend Will Be Larger Than Last Year's
Sep 25Dechra Pharmaceuticals (LON:DPH) Will Pay A Larger Dividend Than Last Year At UK£0.29
Sep 11With EPS Growth And More, Dechra Pharmaceuticals (LON:DPH) Is Interesting
Sep 08Is Dechra Pharmaceuticals PLC (LON:DPH) Worth UK£43.4 Based On Its Intrinsic Value?
Jun 17Is Dechra Pharmaceuticals PLC (LON:DPH) A Smart Choice For Dividend Investors?
Apr 09Dechra Pharmaceuticals (LON:DPH) Has A Pretty Healthy Balance Sheet
Mar 05Are Dechra Pharmaceuticals' (LON:DPH) Statutory Earnings A Good Reflection Of Its Earnings Potential?
Feb 17
Dechra Pharmaceuticals PLC (LON:DPH) Is Going Strong But Fundamentals Appear To Be Mixed : Is There A Clear Direction For The Stock?
Feb 02Did You Participate In Any Of Dechra Pharmaceuticals' (LON:DPH) Fantastic 268% Return ?
Jan 18Calculating The Fair Value Of Dechra Pharmaceuticals PLC (LON:DPH)
Jan 03Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Jun 30 2023 | UK£1m | UK£621k | -UK£28m |
| Mar 31 2023 | n/a | n/a | UK£6m |
| Dec 31 2022 | n/a | n/a | UK£40m |
| Sep 30 2022 | n/a | n/a | UK£49m |
| Jun 30 2022 | UK£2m | UK£597k | UK£58m |
| Mar 31 2022 | n/a | n/a | UK£66m |
| Dec 31 2021 | n/a | n/a | UK£73m |
| Sep 30 2021 | n/a | n/a | UK£64m |
| Jun 30 2021 | UK£3m | UK£551k | UK£56m |
| Mar 31 2021 | n/a | n/a | UK£50m |
| Dec 31 2020 | n/a | n/a | UK£44m |
| Sep 30 2020 | n/a | n/a | UK£39m |
| Jun 30 2020 | UK£2m | UK£517k | UK£34m |
| Mar 31 2020 | n/a | n/a | UK£31m |
| Dec 31 2019 | n/a | n/a | UK£29m |
| Sep 30 2019 | n/a | n/a | UK£30m |
| Jun 30 2019 | UK£3m | UK£500k | UK£31m |
| Mar 31 2019 | n/a | n/a | UK£28m |
| Dec 31 2018 | n/a | n/a | UK£25m |
| Sep 30 2018 | n/a | n/a | UK£30m |
| Jun 30 2018 | UK£3m | UK£500k | UK£36m |
| Mar 31 2018 | n/a | n/a | UK£40m |
| Dec 31 2017 | n/a | n/a | UK£43m |
| Sep 30 2017 | n/a | n/a | UK£35m |
| Jun 30 2017 | UK£3m | UK£490k | UK£26m |
Compensación vs. Mercado: La compensación total de Ian($USD1.31M) está por debajo de la media de empresas de tamaño similar en el mercado UK ($USD3.29M).
Compensación vs. Ingresos: La compensación de Ian ha sido consistente con los resultados de la empresa en el último año.
CEO
Ian Page (62 yo)
22.2yrs
Permanencia
UK£1,037,000
Compensación
Mr. Ian D. Page has been the Chief Executive Officer and Managing Director of Dechra Pharmaceuticals Plc since November 2001 and 1998 respectively and also serves as its Executive Director since June 13, 1...
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| CEO, MD & Executive Director | 22.2yrs | UK£1.04m | 0.36% £ 15.6m | |
| CFO & Executive Director | 4.8yrs | UK£641.00k | 0.010% £ 452.7k | |
| Chief Scientific Officer | 1.5yrs | sin datos | sin datos | |
| Chief Information Officer | 1.6yrs | sin datos | sin datos | |
| Chief People Officer | no data | sin datos | sin datos | |
| President of North America | no data | sin datos | sin datos | |
| Company Secretary | 6.5yrs | sin datos | sin datos |
4.8yrs
Permanencia media
53yo
Promedio de edad
Equipo directivo experimentado: El equipo directivo de DPH se considera experimentado (4.8 años antigüedad media).
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| CEO, MD & Executive Director | 26.6yrs | UK£1.04m | 0.36% £ 15.6m | |
| CFO & Executive Director | 4.3yrs | UK£641.00k | 0.010% £ 452.7k | |
| Independent Non-Executive Director | less than a year | UK£36.00k | sin datos | |
| Senior Independent Director | 7.1yrs | UK£107.00k | 0.0052% £ 227.2k | |
| Independent Non-Executive Chairman | 3.8yrs | UK£207.00k | 0.0033% £ 143.6k | |
| Designated Non-Executive Director | 4.9yrs | UK£72.00k | 0.0012% £ 53.3k | |
| Independent Non-Executive Director | 1.6yrs | UK£73.00k | 0.00053% £ 23.3k |
4.3yrs
Permanencia media
59yo
Promedio de edad
Junta con experiencia: La junta directiva de DPH se considera experimentada (4.3 años de antigüedad promedio).